陈扬超教授 – 生物醫學學院

陈扬超教授

Professor

Ph.D.

39431100

yangchaochen@cuhk.edu.hk

508A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

Publons

ORCID

个人简介

Prof. CHEN Yangchao (陈扬超) is currently a Professor at School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK). He obtained his Ph.D. from Sun Yat-sen University in 2003 and later on was trained as a postdoctoral fellow at University of Washington, Seattle. He has been faculty member as Research Assistant Professor, Assistant Professor and Associate Professor at Faculty of Medicine CUHK since 2007. His research interests include epigenetics in cancer, histone modification particularly methylation, long and short non-coding RNAs, development of novel therapeutics for liver and pancreatic cancer. The ultimate goal of his lab is aimed at the identification of novel diagnostic markers and therapeutic targets for pancreatic and liver cancer.

Research Interests

Identification of novel diagnostic markers and therapeutic targets for digestive cancers including pancreatic cancer and liver cancer.
Identification and characterization of long and short non-coding RNAs with critic roles in cancer.
Identification of cancer associated genes using large scale genetic perturbation screen such as CRISPR/CAS9.
Functional roles of EZH2 in cancer.
Development of novel therapeutics for cancer.

Selected Publications

Wong, C.H., Li, C.H., Tong, J.H.M., Zheng, D., He, Q., Luo, Z., Lou, U.K., Wang, J., To, K.F., Chen, Y. (2022). The establishment of CDK9/RNA PolII/H3K4me3/DNA methylation feedback promotes HOTAIR expression by RNA elongation enhancement in cancer. Mol Ther., 30(4), 1597-1609. doi: 10.1016/j.ymthe.2022.01.038.
Wong, C.H., Lou, U.K., Fung, F.K., Tong, J.H.M., Zhang, C.H., To, K.F., Chan, S.L., Chen, Y. (2022). CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. Mol Cancer., 21(1), 10
Wong, C.H., Lou, U.K., Li, Y., Chan, S.L., Tong, J.H.M., To, K.F., Chen, Y.* (2020). CircFOXK2 Promotes Tumor Growth and Metastasis of Pancreatic Ductal Adenocarcinoma via Complexing with RNA Binding Proteins and Sponging MiR-942. Cancer Res., 80, 2138-2149.
Lou, U.K., Wong, C.H., Chen, Y.* (2020). A simple and rapid colorimetric detection of serum lncRNA biomarkers for diagnosis of pancreatic cancer. RSC Advances. 10, 8087-8092.
Wong, C.H., Li, C.H., He, Q., Chan, S.L., Tong, J.H.M., To, K.F., Lin, L.Z., Chen, Y.* (2020). Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. Cancer Lett., 477, 1-9.
Xu, F., Li, C.H., Wong, C.H., Chen, G.G., Lai, P.B.S., Shao, S., Chan, S.L., Chen, Y.* (2019). Genome-wide screening and functional analysis identifies tumor suppressor long non-coding RNAs epigenetically silenced in hepatocellular carcinoma. Cancer Res., 79, 1305-1317.
Wong, C.H., & Chen, Y. (2019). Clinical significance of exosomes as potential biomarkers in cancer. World Journal of Clinical Cases, 7(2), 171-190.
Li, C.H., Tang, S.C., Wong, C.H., Wang, Y., Jiang, J.D., & Chen, Y. (2018). Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway. European Journal of Pharmacology, 825, 107-118.
Xiao, Z., & Chen, Y. (2017). Identification of Small Molecule Modulators of MicroRNA by Library Screening. Methods in Molecular Biology, 1517, 169-178.
Li, C.H., Xiao, Z., Tong, J., To, K.F., Fang, X., Cheng, A.S.L., & Chen, Y. (2017). EZH2 Coupled with HOTAIR to Silence MicroRNA-34a by the induction of heterochromatin formation in Human Pancreatic Ductal Adenocarcinoma. International Journal of Cancer, 140, 120-129.
Lau, O.C., Shen, B., Wong, C.O., Tjong, Y.W., Lo, C.Y., Wang, H.C., Huang, Y., Yung, W.H., Chen, Y., Fung, M.L., Rudd, J.A., & Yao, X. (2016). TRPC5 channels participate in pressure-sensing in aortic baroreceptors. Nature Communications, 7, 11947.
Xiao, Z., Li, C.H., Chan, S.L., Xu, F., Feng, L., Wang, Y., Jiang, J.D., Sung, J.J.Y., Cheng, C.H.K., & Chen, Y. (2014). A small molecule modulator of the tumor suppressor miRNA-34a inhibits the growth of hepatocellular carcinoma. Cancer Research, 74(21), 6236-6247.
Li, C.H., Xu, F., Chow, S.C., Feng, L., Yin, D., Ng, T.B., & Chen, Y. (2014). Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. European Journal of Cancer, 50, 2560-2569.
Tang, S.C,. & Chen, Y. (2014). Novel Therapeutic Targets for Pancreatic Cancer. World Journal of Gastroenterology, 20(31), 10825-10844.
Xiao, Z.G., Chow, S.C., Li, C.H., Tang, S.C., Tsui, S.K.W., Lin, Z.X., & Chen, Y. (2014). Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. European Journal of Pharmacology, 728, 141-150.
Li, C.H., & Chen, Y. (2013). Targeting long non-coding RNAs in cancers: Progress and perspective. International Journal of Biochemistry & Cell Biology, 45(8), 1895-1910.
Li, C.H., To, K.F., Tong, J.H., Xiao, Z., Xia, T., Lai, P.B., Chow, S.C., Zhu, Y.X., Chan, S.L., Marquez, V.E., & Chen, Y. (2013). Enhancer of Zeste Homolog 2 Silences microRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin. Gastroenterology, 144, 1086-1097.
Cheng, A.S.L., Lau, S.S., Chen, Y., Kondo, Y., Li, M.S., Feng, H., Ching, A.K., Cheung, P.K., Wong, K.H., Jin, H., Choy, R., Yu, J., To, K.F., Wong, N., Huang, T.H., & Sung, J.J.Y. (2011). EZH2–mediated concordant repression of Wnt antagonists promotes β- catenin –dependent hepatocarcinogenesisi. Cancer Research, 71, 4028-4039.
Wong, W.T., Tian, X.Y., Chen, Y., Leung, F.P., Wong, S.L., Lee, H.K., Ng, C.F., Yao, X., Vanhoutte, Tipoe G., & Huang, Y. (2010). COX-2 up-regulation and prostaglandin F2α mediate bone morphogenic protein 4-induced endothelial dysfunction in hypertension. Circulation Research, 107, 984-991.

Grants

RGC – General Research Fund [PI; 01-Jan-20]: “Characterization of the anti-metastatic function of POU4F3 in pancreatic ductal adenocarcinoma and delineate its underlying mechanism” (HK$953,013).
RGC – General Research Fund [PI; 01-Jan-19]: “Characterization of the novel KRAS-driven STK32B kinase and identification of selective inhibitors for therapeutic intervention in pancreatic cancer” (HK$868,956).
广州循证医药科技有限公司 [PI; 25-Jan-18 to 24-Jan-20]: “片仔癀胶囊治疗中晚期原发性肝癌(肝热血瘀证)的临床研究: 血清游离DNA与外泌体检测” (RMB950,000).
RGC – General Research Fund [PI; 01-Jan-18 to 31-Dec-20]: “Genome-wide identification of circular RNAs with critical roles in pancreatic ductal adenocarcinoma” (HK$1,225,785).
Guangzhou Evidence-based Medicine Tech. Co. Ltd. [PI; 15-Jul-17 to 31-Dec-18]: “Investigation of the Cell Free DNAs and Exosome in Serum Samples of HCC Patients Treated with Pianzaihuan” (HK$1,159,000).
RGC – General Research Fund [PI; 01-Jan-17 to 31-Dec-19]: “Identification of Novel Tumor Suppressor Long Non-coding RNAs Epigenetically Silenced in Hepatocellular Carcinoma” (HK$1,000,716).
National Natural Science Foundation of China (NSFC) [PI; 01-Jan-17 to 30-Dec-20]: “Identification of Noel Therapeutic Targets for Pancreatic Cancer Genome-wide RNAi Screening in Vivo (Awarded amount: RMB570,000; no funding transferred to CUHK)” (RMB570,000).
Innovation & Technology Commission-Innovation and Technology [PI; 01-Jun-15 to 30-Nov-16]: “Metabolism and Pharmacokinetic Analysis of a Small Molecule Modulator of Tumor Suppressor microRNA-34a” (HK$1,398,664).
RGC – General Research Fund [PI; 01-Jan-15 to 31-Dec-17]: “Characterization of a Novel Long Non-coding RNA AK311005 with Potential Tumor Suppressive Role in Pancreatic Ductal Adenocarcinoma” (HK$763,494).
National Natural Science Foundation of China (NSFC) [PI; 01-Jan-15 to 31-Dec-18]: “非编码小RNA-34a(microRNA-34a)小分子调控剂的抗肝癌效应及作用机制研究 (Project Awarded: RMB 750,000; no funding transferred to Hong Kong)” (RMB750,000).
Horizontal Project Funded by Enterprise “横向项目” [PI; 31-Oct-14 to 30-Jun-16]: “Role of microRNA in the Multiple Target Effect of Berberine (Project Awarded: RMB 300,000; no funding transferred to Hong Kong)” (RMB300,000).
SZ Science & Technology Innovation Commission – SZ R & D Funds of Science and Technology [PI; 03-Jan-14 to 31-Dec-14]: “The Molecular Mechanism of Polycomb Group Protein EZH2 Regulation on miR-34a in Pancreatic Cancer and its Significance (Project Awarded: RMB45,000; no funding transferred to Hong Kong)” (RMB45,000).
RGC – General Research Fund [PI; 01-Jan-14 to 31-Dec-16]: “Identification and Functional Characterization of Long Non-coding RNAs Associated with Pancreatic Ductal Adenocarcinoma” (HK$1,299,049).